Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Apyx Medical CorporationNASDAQ: APYX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$429K, compared with -$2.61M a year earlier. Trailing-twelve-month EBITDA was -$2.44M.

Context

  • EBITDA amounted to 8.7% of revenue in FY2025, down 26.2 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$3.11M (+32.3%) for the fiscal year ending Dec 2026, a slowdown from the +72.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$429K-189.0% QoQ
Last fiscal yearDec 2025
-$4.59M+72.7% YoY
LTMMar 2026
-$2.44M+81.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.6%+4.4%-79.2 pp
1 year+72.7%+32.3%-40.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(4.59M) USD
Year-over-year change
+72.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 EBITDA of -$2.44M is the 3rd highest of the 8 companies compared; the peer median is -$31.22M.
  • Its year-over-year change of +81.8% is the 2nd highest of 8, against a peer median of +25.1%.
  • EBITDA amounts to 4.4% of revenue for APYX, versus a peer median of 91.7%.
APYX Competitors Peer median
EBITDA for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDEXPro-Dex, Inc.LTM Mar 2026$19.63M +41.4%+27.1%26.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$11.81M +465.2%—9.7%
APYXApyx Medical CorporationLTM Mar 2026-$2.44M +81.8%—4.4%
VANIVivani Medical, Inc.LTM Mar 2026-$26.64M -14.1%——
SERASera Prognostics, Inc.LTM Mar 2026-$31.22M +2.8%—54764.9%
RCELAVITA Medical, Inc.LTM Mar 2026-$37.72M +25.1%—52.1%
LUCDLucid Diagnostics Inc.LTM Mar 2026-$44.12M +27.6%—859.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-$45.12M -8.6%—131.2%
Peer median (excluding APYX) -$31.22M+25.1%+27.1%91.7%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.52M44.51M52.35M48.1M52.84M
Cost of Revenue14.92M15.38M18.59M18.74M33.81M
Gross Profit33.6M29.13M33.76M29.36M19.03M
Gross Margin69.3%65.4%64.5%61.0%36.0%
Research & Development4.32M4.54M4.84M5.08M3.37M
Selling, General & Admin43.73M48.15M48.87M43.13M36.12M
Operating Expenses48.05M52.69M51.02M48.21M25.48M
Depreciation & Amortization903K890K692K599K655K
EBITDA(13.91M)(22.01M)(18.11M)(16.8M)(4.59M)
EBITDA Margin-28.7%-49.4%-34.6%-34.9%-8.7%
Operating Income(14.45M)(23.56M)(17.26M)(18.85M)(6.45M)
Operating Margin-29.8%-52.9%-33.0%-39.2%-12.2%
Interest Income11K157K921K1.61M1.11M
Interest Expense10K15K2.48M5.91M5.59M
Other Income / Expenses(372K)651K(4.02M)(4.46M)(4.39M)
Income Before Tax(14.82M)(22.91M)(21.28M)(23.31M)(10.84M)
Pre-Tax Margin-30.5%-51.5%-40.7%-48.5%-20.5%
Income Tax Expense380K367K(2.43M)252K270K
Net Income(15.17M)(23.18M)(18.71M)(23.46M)(11.21M)
Net Margin-31.3%-52.1%-35.7%-48.8%-21.2%
EPS (Basic)(0.44)(0.67)(0.54)(0.66)(0.27)
EPS (Diluted)(0.44)(0.67)(0.54)(0.66)(0.27)
Weighted Avg Shares34.33M34.52M34.62M35.54M42.16M
Weighted Avg Shares (Diluted)34.33M34.52M34.62M35.54M42.16M

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.